Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization
Yukinobu Watanabe MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Masahiro Ogawa MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Address correspondence to Masahiro Ogawa, MD, PhD, Department of Gastroenterology, Nihon University Hospital, 1-6 Kanda, Surugadai, Chiyoda-ku, Tokyo 101-8309, Japan. E-mail: [email protected]Search for more papers by this authorMariko Kumagawa MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorMidori Hirayama MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorTakao Miura MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorNaoki Matsumoto MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorHiroshi Nakagawara MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorToshiki Yamamoto MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorMitsuhiko Moriyama MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorYukinobu Watanabe MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Masahiro Ogawa MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Address correspondence to Masahiro Ogawa, MD, PhD, Department of Gastroenterology, Nihon University Hospital, 1-6 Kanda, Surugadai, Chiyoda-ku, Tokyo 101-8309, Japan. E-mail: [email protected]Search for more papers by this authorMariko Kumagawa MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorMidori Hirayama MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorTakao Miura MD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorNaoki Matsumoto MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorHiroshi Nakagawara MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorToshiki Yamamoto MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorMitsuhiko Moriyama MD, PhD
Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan
Search for more papers by this authorAbstract
Objectives
We aimed to investigate whether contrast-enhanced ultrasound (CEUS) could be useful for early evaluation of the treatment response to transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC).
Methods
This study retrospectively selected HCCs in which homogeneous retention of iodized oil was confirmed on non–contrast-enhanced computed tomography performed immediately after TACE. Therapeutic responses of HCCs were evaluated by CEUS 1 to 2 days after TACE and by contrast-enhanced computed tomography (CECT) approximately 4 weeks after TACE. We investigated the noninferiority of CEUS 1 to 2 days after TACE to CECT approximately 4 weeks after TACE in terms of the diagnostic accuracy of the therapeutic response to TACE on HCC.
Results
Eighty-nine HCCs were enrolled in this study between April 2014 and June 2016. A complete response was observed in 57 of 89 nodules (64.0%), and an incomplete response was observed in the remaining 32 nodules (36.0%). The accuracy rates for CEUS 1 to 2 days after TACE and CECT approximately 4 weeks after TACE in the therapeutic effect of TACE on HCCs were 83.1% (95% confidence interval, 73.7%–90.2%) and 83.1% (95% confidence interval, 73.7%–90.2%), respectively. The difference in diagnostic accuracy between methods was 0%, which was below the predetermined noninferiority limit of 15%, and CEUS 1 to 2 days after TACE was noninferior to CECT approximately 4 weeks after TACE.
Conclusions
Our results suggest that CEUS is a useful modality for early therapeutic evaluation of TACE for HCC, and we can thus plan the next treatment strategies for HCC within a few days after TACE.
References
- 1Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. Cancer 1995; 75: 2427–2434.
10.1002/1097-0142(19950515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 2Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429–442.
- 3Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–1171.
- 4Llovet JM, Real MI, Monyaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–1739.
- 5Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237–257.
- 6Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373–382.
- 7Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984–992.
- 8Cioni D, Lencioni R, Bartolozzi C. Therapeutic effect of transcatheter arterial chemoembolization on hepatocellular carcinoma: evaluation with contrast-enhanced harmonic power Doppler ultrasound. Eur Radiol 2000; 10: 1570–1575.
- 9Morimoto M, Shirato K, Sugimori K, et al. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181: 65–69.
- 10Numata K, Tanaka K, Kiba T, et al. Using contrast-enhanced sonography to assess the effectiveness of transcatheter arterial embolization for hepatocellular carcinoma. AJR Am J Roentgenol 2001; 176: 1199–1205.
- 11Kim SH, Lee WJ, Lim HK, Lim JH. Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist Tomogr 2007; 31: 198–203.
- 12Hunt SJ, Yu W, Weintraub J, Prince MR, Konthary N. Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 2009; 20: 30–38.
- 13Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 532–540.
- 14Bartolozzi C, Lencioni R, Caramella D, Falaschi F, Cioni R, DiCoscio G. Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1994; 191: 123–128.
- 15Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 1992; 182: 709–713.
- 16Xia Y, Kudo M, Minami Y, et al. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of Sonazoid-enhanced harmonic sonography. Oncology 2008; 75: 99–105.
- 17Liu M, Lin MX, Xu ZF, et al. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST. Eur Radiol 2015; 25: 2502–2511.
- 18Salvaggio G, Campisi A, Lo GV, Cannella I, Meloni MF, Caruso G. Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT. Abdom Imaging 2010; 35: 447–453.
- 19Cho YZ, Park SY, Choi EH, et al. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study. Clin Mol Hepatol 2015; 21: 165–174.
- 20Minami Y, Kudo M. Imaging modalities for assessment of treatment response to nonsurgical hepatocellular carcinoma therapy: contrast-enhanced US, CT, and MRI. Liver Cancer 2015; 4: 106–114.
- 21Zeno S, Tudor M, Pompilia R, et al. Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma. Med Ultrason 2016; 18: 96–102.
- 22Paul SB, Dhamija E, Gamanagatti SR, et al. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: comparison of contrast-enhanced ultrasound with multiphase computed tomography. Diagn Interv Imaging 2017; 98: 253–260.
- 23Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, Kudo M. Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases. J Med Ultrason 2012; 39: 15–19.
- 24Kono Y, Lucidarme O, Choi SH, et al. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 57–65.
- 25Sugimoto K, Moriyasu F, Saito K, et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med 2012; 31: 529–538.
- 26Schacherer D, Girlich C, Zorger N, et al. Sono-hepatic-arteriography (Sono-HA) in the assessment of hepatocellular carcinoma in patients undergoing transcatheter arterial chemoembolization (TACE). Ultraschall Med 2010; 31: 270–275.
- 27Lekht I, Nayyar M, Luu B, et al. Intra-arterial contrast-enhanced ultrasound (IA CEUS) for localization of hepatocellular carcinoma (HCC) supply during transarterial chemoembolization (TACE): a case series. Abdom Radiol 2017; 42: 1400–1407.
- 28Shiozawa K, Watanabe M, Ikehara T, et al. Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. World J Hepatol 2018; 10: 95–104.
- 29Boily G, Villeneuve JP, Lacoursière L, et al. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) 2015; 17: 52–65.
- 30Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6–25.
- 31Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163: 345–351.
- 32Lee JA, Jeong WK, Kim Y, et al. Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging. Eur J Radiol 2013; 82: 569–576.
- 33Takizawa K, Numata K, Morimoto M, et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed 1 day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol 2013; 82: 1471–1480.
- 34Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol 2011; 2011: 974514.
- 35Seehofer D, Nebrig M, Denecke T, et al. Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. Clin Transplant 2012; 26: 764–774.
- 36Manini MA, Sangiovanni A, Martinetti L, et al. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl 2015; 21: 1259–1269.
- 37Hanada M, Baba A, Tsutsumishita Y, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by including platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 2009; 64: 473–483.
- 38Leen E, Averkiou M, Arditi M, et al. Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials. Eur Radiol 2012; 22: 1442–1450.
- 39Ding H, Kudo M, Onda H, et al. Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 2001; 221: 721–730.
- 40Moschouris H, Malagari K, Papadaki MG, et al. Short-term evaluation of liver tumors after transarterial chemoembolization: limitations and feasibility of contrast-enhanced ultrasonography. Abdom Imaging 2011; 36: 718–728.
Citing Literature
